Antibody-based proteomics for esophageal cancer: Identification of proteins in the nuclear factor-κB pathway and mitotic checkpoint

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1612-1622

  Uemura, Norihisa ^a,b,c   Nakanishi, Yukihiro ^a   Kato, Hoichi ^b   Nagino, Masato ^c   Hirohashi, Setsuo ^a   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 SPINDLE CHECKPOINT PROTEIN; CALCIUM BINDING PROTEIN; CASPASE 10; CELL CYCLE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAD2L1 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR PROTEIN;

ARTICLE; CHEMISTRY; DNA MICROARRAY; ENZYME IMMUNOASSAY; ESOPHAGUS; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROTEIN MICROARRAY; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CARCINOMA, SQUAMOUS CELL; CASPASE 10; CELL CYCLE PROTEINS; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1;

EID: 70149097761     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01230.x     Document Type: Article

References (51)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-41.
2. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
3. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 2003; 29: 525-32.
4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
5. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-23.
6. Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH. Molecular biology of esophageal cancer. Onkologie 2004; 27: 200-6.
7. Hatakeyama H, Kondo T, Fujii K et al. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 2006; 6: 6300-16.
8. Liu WL, Zhang G, Wang JY et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008; 375: 440-5.
9. Homs MY, Kuipers EJ, Siersema PD. Palliative therapy. J Surg Oncol 2005; 92: 246-56.
10. Katlic MR, Wilkins EW Jr, Grillo HC. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 1990; 99: 929-38.
11. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 2000; 6: 4249-52.
12. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005; 129: 1454-63.
13. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas - a tool for pathology. J Pathol 2008; 216: 387-93.
14. Sobin L, Wittekind C. UICC TNM Classification of Malignant Tumors, 6th edn. New York: Wiley-Liss, 2002.
15. Chen G, Gharib TG, Huang CC et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1: 304-13.
16. Varambally S, Yu J, Laxman B et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.
17. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-30.
18. Uemura N, Nakanishi Y, Kato H et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer 2009; 124: 2106-15.
19. Nishimori T, Tomonaga T, Matsushita K et al. Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. Proteomics 2006; 6: 1011-18.
20. Madoz-Gurpide J, Canamero M, Sanchez L, Solano J, Alfonso P, Casal JI. A proteomics analysis of cell signaling alterations in colorectal cancer. Mol Cell Proteomics 2007; 6: 2150-64.
21. Smith L, Watson MB, O'Kane SL, Drew PJ, Lind MJ, Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther 2006; 5: 2115-20.
22. Celis JE, Moreira JM, Cabezon T et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 2005; 4: 492-522.
23. Ingvarsson J, Wingren C, Carlsson A et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008; 8: 2211-19.
24. Orchekowski R, Hamelinck D, Li L et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res 2005; 65: 11 193-202.
25. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am J Pathol 2006; 168: 93-103.
26. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003; 3: 56-63.
27. Knezevic V, Leethanakul C, Bichsel VE et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 2001; 1: 1271-8.
28. Weber A, Hengge UR, Stricker I et al. Protein microarrays for the detection of biomarkers in head and neck squamous cell carcinomas. Hum Pathol 2007; 38: 228-38.
29. Tannapfel A, Anhalt K, Hausermann P et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 2003; 201: 238-49.
30. Ellmark P, Ingvarsson J, Carlsson A, Lundin BS, Wingren C, Borrebaeck CA. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol Cell Proteomics 2006; 5: 1638-46.
31. Hoyt MA. A new view of the spindle checkpoint. J Cell Biol 2001; 154: 909-11.
32. Wang X, Jin DY, Wong YC et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000; 21: 2293-7.
33. Tanaka K, Nishioka J, Kato K et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 2001; 92: 952-8.
34. Wang X, Jin DY, Ng RW et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002; 62: 1662-8.
35. Li GQ, Li H, Zhang HF. Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 2003; 9: 1972-5.
36. Jeong SJ, Shin HJ, Kim SJ et al. Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Res 2004; 64: 8666-73.
37. Tanaka K, Mohri Y, Ohi M et al. Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5- fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol) 2008; 20: 639-46.
38. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002; 62: 13-17.
39. Grabsch H, Takeno S, Parsons WJ et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J Pathol 2003; 200: 16-22.
40. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004; 3: 661-9.
41. Doree M, Hunt T. From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 2002; 115: 2461-4.
42. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004; 116: 221-34.
43. Hansel DE, Dhara S, Huang RC et al. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Am J Surg Pathol 2005; 29: 390-9.
44. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076-82.
45. Abdel-Latif MM, O'Riordan J, Windle HJ et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239: 491-500.
46. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-8.
47. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6.
48. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-68.
49. Wang H, Wang P, Sun X et al. Cloning and characterization of a novel caspase-10 isoform that activates NF-kappa B activity. Biochim Biophys Acta 2007; 1770: 1528-37.
50. Bouwmeester T, Bauch A, Ruffner H et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004; 6: 97-105.
51. Czabanka M, Korherr C, Brinkmann U, Vajkoczy P. Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. Front Biosci 2008; 13: 7243-9.